{
    "clinical_study": {
        "@rank": "137690", 
        "arm_group": [
            {
                "arm_group_label": "Firebird2\u00ae DES", 
                "arm_group_type": "Active Comparator", 
                "description": "Device:Firebird2\u00ae DES The Firebird2\u00ae rapamycin-eluting stent (Firebird2\u00ae DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length."
            }, 
            {
                "arm_group_label": "Tivoli\u00ae DES", 
                "arm_group_type": "Experimental", 
                "description": "Device:Tivoli\u00ae DES The Tivoli\u00ae DES is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, multi-center, open label, randomized study to evaluate the efficacy\n      and safety of The TIVOLI Biodegradable polymer Rapamycin-Eluting Stent comparing with The\n      FIREBIRD2\u2122 Rapamycin-eluting Stent (DES) for Treatment Coronary Revascularization."
        }, 
        "brief_title": "Evaluate Safety And Effectiveness Of The Tivoli\u00ae DES and The Firebird2\u00ae DES For Treatment Coronary Revascularization", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ischemic Heart Disease", 
            "Myocardial Ischemia", 
            "Coronary Artery Lesions,Primary", 
            "Coronary Disease", 
            "Acute Coronary Syndrome", 
            "Furcation Lesion of Coronary Artery"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Myocardial Ischemia", 
                "Coronary Artery Disease", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Ischemia", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 The patient must be \u226518 of age;\n\n               -  Symptomatic ischemic heart disease and/or objective evidence of myocardial\n                  ischemia including chronic stable coronary artery disease, or acute coronary\n                  syndrome including non-ST-elevation and ST-elevation myocardial infarction;\n\n               -  Acceptable candidate for CABG;\n\n               -  The patient is willing to comply with specified follow-up evaluations;4.Patients\n                  who agree to accept the follow-up visits.\n\n               -  Patients can understand the study objectives psychologically and linguistically\n                  and show the sufficient compliance to the study protocol. Patients present\n                  acceptance of the risks and benefits described in the informed consent form.\n\n        Angiographic Inclusion criteria:\n\n          -  At least one lesion with a diameter stenosis >70% or more suitable for coronary stent\n             implantation in a vessel with a reference diameter ranging from 2.5 mm to 4.0 mm;\n\n          -  Patients with multi-lesion or multi-vessel coronary disease, must have successful\n             treatment (<30% diameter stenosis visual estimate) of the first treated lesion prior\n             to treatment of other lesions at the same brand of stent. Staged (planned) procedures\n             must be performed within 30 days of the index procedure.\n\n        Exclusion Criteria:\n\n          -  General Exclusion Criteria\n\n               -  Pregnant or nursing patients and those who plan pregnancy in the period up to 1\n                  year following index procedure.\n\n               -  Patient has a history of bleeding diathesis or coagulopathy or patients in whom\n                  anti-platelet and/or anticoagulant therapy is contraindicated or in which\n                  patient will not be able to comply with dual antiplatelet therapy for at least 1\n                  year;\n\n               -  Patient has other medical illness (e.g., cancer, known malignancy, congestive\n                  heart failure, organ transplant recipient or candidate) or known history of\n                  substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance\n                  with the protocol, confound the data interpretation or is associated with a\n                  limited life expectancy (i.e., less than 1 year);\n\n               -  Left ventricular function <40%;\n\n               -  Cardiogenic shock or hemodynamic compromise requiring pressors and/or inotropes\n                  or mechanical support;\n\n               -  Patient has a known hypersensitivity or contraindication to aspirin, heparin,\n                  clopidogrel/ticlopidine, stainless steel alloy, cobalt chromium, Rapamycinry ,\n                  styrene-butylenes-styrene or poly-lactic acid (PLA) polymer, and/or contrast\n                  sensitivity that cannot be adequately pre-medicated;\n\n               -  Any significant medical condition which in the Investigator's opinion may\n                  interfere with the patient's optimal participation in the study;\n\n               -  Currently participating in another investigational drug or device study or\n                  patient in inclusion in another investigational drug or device study during\n                  follow-up.\n\n               -  Existing impairment in liver and kidney.\n\n               -  Extremely tortuous and/or calcification lesions.\n\n        Angiographic exclusion criteria:\n\n        \u2022 Two or more chronic total occlusions in the proximal half of the epicardial coronary\n        artery which cannot be recannalized."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2790", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681381", 
            "org_study_id": "I-LOVE-IT2"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Firebird2\u00ae DES", 
                    "Tivoli\u00ae DES"
                ], 
                "description": "Device:Tivoli\u00ae DES The Tivoli\u00ae DES drug eluting stent(Tivoli\u00ae DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10\u300115\u300118\u300121\u300125\u300130\u300135 mm and diameters of 2.5\u30012.75\u30013.0\u30013.5\u30014.0 mm.", 
                "intervention_name": "Tivoli\u00ae DES", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Firebird2\u00ae DES", 
                    "Tivoli\u00ae DES"
                ], 
                "description": "The Firebird2\u00ae rapamycin-eluting stent (Firebird2\u00ae DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.", 
                "intervention_name": "Firebird2\u00ae DES", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 20, 2013", 
        "location": {
            "contact": {
                "email": "hanyaling@263.net", 
                "last_name": "Han Yaling, Prof.", 
                "phone": "(86-024) 28851120"
            }, 
            "facility": {
                "address": {
                    "city": "Shenyang", 
                    "country": "China", 
                    "state": "Liaoning", 
                    "zip": "86-110016"
                }, 
                "name": "The General Hospital of Shenyang Military Region"
            }, 
            "investigator": {
                "last_name": "Han Yaling, Prof.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Open Label, Randomized Study to Evaluate Safety And Effectiveness Of The Tivoli\u00ae Biodegradable Polymer Rapamycin-Eluting Stent and The FIREBIRD2\u00ae Rapamycin-Eluting Coronary CoCr Stent For Treatment Coronary Revascularization", 
        "overall_official": {
            "affiliation": "The General Hospital of Shenyang Military Region", 
            "last_name": "Han Yaling, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ischemia-driven Target Lesion Failure (TLF) which is a composite of cardiac death, myocardial infarction (Q and non-Q wave) and target lesion revascularization (TLR) at 12 months post-procedure.", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681381"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Essen Technology (Beijing) Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Essen Technology (Beijing) Co., Ltd.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}